GENE ONLINE|News &
Opinion
Blog

JAK Inhibitor
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
GSK to Acquire Biopharmaceutical Company Sierra Oncology for $1.9B
2022-04-17
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
2022-02-16
FDA Approves Incyte’s Jakafi for Chronic Graft-Versus-Host Disease
2021-09-23
Pfizer’s JAK1 Inhibitor Impresses in Phase 3 Atopic Dermatitis Trial
2020-11-12
Pfizer Announces Positive Top-Line Results for JAK Inhibitor in Ankylosing Spondylitis Trial
2020-11-08
Lilly, Incyte Gaining Ground in the Fight against Alopecia Areata
2020-11-01
Torii Pharma’s Corectim Ointment Features in Japan’s NHI Drug Price List
2020-04-26
Pfizer’s Dupixent Rival Meets Endpoints in Atopic Dermatitis Trial
2020-04-05
LATEST
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
Seasonal Skin Irritations Rise, Driving Demand for Accessible and Easy-to-Use Treatments
2025-05-14
Tirzepatide Users See 20.2% Average Weight Loss in Obesity Management Trial
2025-05-14
iMMagine-1 Phase 2 Study Provides Data on Investigational Matter Characteristics and Behavior
2025-05-14
Novo Nordisk Partners with Septerna in $2.2 Billion Deal to Develop Oral Obesity Drugs
2025-05-14
SMA: Researchers Explore In Utero Treatment Methods to Mitigate Muscle Weakness Before Birth
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top